Form 4: Alkermes CEO Richard Pops Reports Stock Option Grant in Form 4 Filing
SEC Form 4 Filing
Alkermes CEO Richard Pops reports the acquisition of 274,328 employee stock options in a recent Form 4 filing with the SEC.
Summary
- Richard F. Pops, CEO and Director of Alkermes plc, filed a Form 4 with the SEC on February 27, 2024.
- The filing reports the acquisition of 274,328 employee stock options on February 26, 2024, with an exercise price of $30.04.
- These options vest in four equal annual installments commencing on February 26, 2025, and expire on February 26, 2034.
- The filing also details existing employee stock options held by Pops, with varying exercise prices and expiration dates.
- A Power of Attorney document is included, granting certain individuals the authority to act on Pops' behalf in matters related to SEC filings.
Sentiment
Score: 6
Explanation: The document is a routine SEC filing related to executive compensation. It doesn't contain any information that would significantly impact investor sentiment positively or negatively. It is a neutral event.
Positives
- The grant of stock options to the CEO aligns his interests with those of shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
- The Power of Attorney ensures timely and accurate SEC filings.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Form 4 filings are a standard part of corporate governance, providing transparency into the transactions of company insiders. The granting of stock options is a common practice to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the pharmaceutical industry, used by companies like Amgen, Biogen, and Vertex to incentivize performance and retain key personnel.
- The vesting schedules and exercise prices are generally in line with industry norms, designed to reward long-term value creation.
- Power of Attorney arrangements for SEC filings are standard practice, ensuring compliance and efficiency.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO to drive long-term value.
- Employees may see the CEO's stock ownership as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| February 6, 2024 | Date of Power of Attorney execution. |
| February 26, 2024 | Date of stock option acquisition. |
| February 27, 2024 | Date of Form 4 filing. |
| February 26, 2025 | First vesting date for the newly acquired stock options. |
| February 26, 2034 | Expiration date for the newly acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.